معرفی
Wei Xu is a Professor in the Department of Oncology at the University of Wisconsin-Madison. His research focuses on epigenetic mechanisms regulating estrogen receptor (ER) signaling and histone arginine methylation in cancer progression, particularly breast cancer. He leads studies on CARM1/PRMT4 and its role in chromatin modifications, tumor metabolism, and therapeutic resistance. His work combines molecular biology, biochemistry, and mouse genetics to uncover mechanisms underlying cancer pathogenesis and develop targeted therapies.
Education
- B.S., Beijing University, 1991
- M.S., Institute of Biophysics (Academia Sinica), 1994
- Ph.D., University of Iowa, 1999
- Postdoctoral Training: The Salk Institute for Biological Sciences, 2000-2003
Research Interests
- Epigenetic regulation of ER signaling in breast cancer
- Role of histone arginine methylation in cancer
- Molecular mechanisms of mesenchymal stem cell differentiation
- Development of epigenetic drugs targeting CARM1
His lab investigates the CARM1-H3R17me2-Ctr9 axis in stem cell lineage commitment and osteogenesis, linking epigenetic changes to bone diseases like osteoporosis. Recent work highlights CARM1's role in metabolic reprogramming and its therapeutic potential in ER-positive and triple-negative breast cancers.
Advising & Grants
- Current advisee: Kasey Mitchell (PhD in progress)
- NIH-funded studies on chromatin regulators and tumor metabolism
Labs & Collaborations
Operates a multidisciplinary lab integrating genomic approaches, mouse models, and chemical biology. Collaborates with teams studying tumor microenvironment dynamics and drug development for epigenetic targets.
